Marketwire -- Mechelen, Belgium and Los Angeles, USA; 29 October 2008 - Galapagos NV (Euronext: GLPG) and CHDI Foundation, Inc., a non-profit organization pursuing treatments for Huntington's disease (HD), announced today new collaboration agreements focused on developing novel assays for drug discovery and evaluating known compounds as potentially new therapeutic approaches for HD. Total value of the contracts for Galapagos is $1 million (EUR 0.8 million) over 1.5 years.
